Trials / Completed
CompletedNCT00436059
The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Vejle Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the the study is to investigate the changes in bone remodeling during Velcade treatment.
Detailed description
20 patients will be included in the study over a 2 year period. Before, during and after treatment we will measure NTX-I, CTX-I, CTX-MMP, bALP, DKK-1, PINP, TRAcP and PTH. NTX, CTX and CTX-MMP are measured to estimate bone degradation. TRAcP is measured to estimate the activity of the osteoclasts. bALP and DKK-1 is measured to evaluate the activity of the osteoblasts and PINP is measured as a marker of new bone formation. PTH is measured in order to evaluate if the positive effects that is observed in bone formation in relations to velcade treatment is due to the pulsative way velcade is administered. The effect of the velcade treatment will be evaluated by x-ray, bone marrow and m-component.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bortezomib |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2007-02-16
- Last updated
- 2009-07-08
Locations
2 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00436059. Inclusion in this directory is not an endorsement.